Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.59 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983185 | 0.92 | PTGER4 (0.49) | PTGER4PTGER2NR4A1NR4A2NR4A3 | |
| SCHEMBL5188816 | 0.92 | PTGER4 (0.70) | PTGER4PTGER2NR4A1NR4A2NR4A3 | |
| SCHEMBL692172 | 0.92 | PTGER4 (0.70) | PTGER4PTGER2NR4A1NR4A2NR4A3 | |
| SCHEMBL19714256 | 0.89 | PTGER4 (0.73) | PTGER4PTGER2PTGDR | |
| SCHEMBL691395 | 0.89 | PTGER4 (0.73) | PTGER4PTGER2PTGDR | |
| SCHEMBL692553 | 0.86 | PTGER4 (0.64) | PTGER4PTGER2NR4A2 | |
| SCHEMBL3980243 | 0.84 | NR4A2 (0.61) | NR4A1NR4A2NR4A3 | |
| SCHEMBL22076482 | 0.84 | PTGER4 (0.61) | PTGER4PTGER2NR4A2 | |
| SCHEMBL692175 | 0.84 | PTGER4 (0.61) | PTGER4PTGER2NR4A2 | |
| SCHEMBL691363 | 0.84 | PTGER4 (0.63) | PTGER4PTGER2NR4A2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756042-B1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8084476-B2 | Substituted methyl aryl or heteroaryl amide compounds | RAQUALIA PHARMA INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084476-B2 | Substituted methyl aryl or heteroaryl amide compounds | RAQUALIA PHARMA INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084476-B2 | Substituted methyl aryl or heteroaryl amide compounds | RAQUALIA PHARMA INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | RAQUALIA PHARMA INC. (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | RAQUALIA PHARMA INC. (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | RAQUALIA PHARMA INC. (JP) | 2009-06-25 | — | — | US | disclosed |
| US-7534914-B2 | Substituted methyl aryl or heteroaryl amide compounds | REQUALIA PHARMA INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534914-B2 | Substituted methyl aryl or heteroaryl amide compounds | REQUALIA PHARMA INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534914-B2 | Substituted methyl aryl or heteroaryl amide compounds | REQUALIA PHARMA INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | PTGER1, PTGER2, PTGER3 | PTGER4 14/4885PTGER2 2/4885NR4A1 334/4885 |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PTGER1, PTGER2, PTGER3 | PTGER4 14/4885PTGER2 2/4885NR4A1 334/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | PTGER4 1/4885PTGER2 2/4885NR4A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.